ISPOR Europe 2019

Copenhagen schedule

Monday 4 November 2019

Posters

Display hours	Session	Code	Title	Authors
10:30-14:00	PNS: No specific disease	PNS217	How central limit theorem relates to the selection of distributions for probabilistic sensitivity analysis	Hale O, Lee D
10:30-14:00	PNS: No specific disease	PNS260	Inclusion of new strategies in the UK’s Cancer Drug Fund: what was decided in France?	Trancart M, Almond C, Sullivan W
15:30-19:00	PCN: Cancer	PCN226	The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK	Ntais D, Batteson R, Hart R, Hemstock M, Lee D
15:30-19:00	PCN: Cancer	PCN345	A review of differences in decision-making across NICE health technology assessments of nivolumab	Horscroft J, Casson J, Sullivan W, Ntais D, Kiff C, Tyas D
15:30-19:00	PCN: Cancer	PCN346	Mean versus median: what does NICE consider to be the most appropriate statistic for estimating short life expectancy to satisfy end-of-life criteria?	Raad A, Lee D
15:30-19:00	PCN: Cancer	PCN380	A targeted review evaluating uncertainty in single technology appraisal submissions for treatments approved for use since the introduction of the ‘new’ Cancer Drugs Fund	Critchlow S, Lilley C, Gladwell D, Akehurst RL, Palmer S, Trevor N, Adedokun L, Lee JM
15:30-19:00	PCN: Cancer	PCN472	Patient reported health state utilities in cutaneous t-cell lymphoma (CTCL) – an analysis of EQ-5D and Skindex-29 data collected from the Alcanza trial	Podkonjak T, McCarthy G, Cranmer H, Birnie R
15:30-19:00	PCN: Cancer	PCN530	The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK	Ntais D, Batteson R, Hart R, Hemstock M, Lee D

Workshop

Time	Code	Title	Discussion leaders	Location
17:00-18:00	W8	Improving efficiency in HTA: the role of open source models and more advanced software choice	Raquel Aguiar-Ibáñez, Gianluca Baio, Dawn Lee, R. Brett McQueen	C1 M1

Tuesday 5 November 2019

Posters

Display hours	Session	Code	Title	Authors
10:30-14:00	PDB: Diabetes/Endocrine/Metabolic Disorders	PDB32	Would a cohort-level approach to cost-effectiveness modelling have led to a different decision in an important NICE appraisal for obesity patients?	Metry A, Sullivan W, Kearns B, Bullement A
15:45-19:00	PMU: Multiple Diseases	PMU82	Varying willingness-to-pay based on disease burden: Impact on health technology assessment outcomes of specialist drugs in the Netherlands	Schurer M, Vossen CY, van Keep M, Horscroft J, Moorhouse JA, Chapman AM, Akehurst RL
15:30-19:00	PMU: Multiple Diseases	PMU114	Specialised health technology assessment processes for very rare diseases: past, present and future	Akehurst RL, Moorhouse JA, Jones E, Mason N, Schurer M, Chapman AM, Horscroft J

Wednesday 6 November 2019

Poster

Display hours	Session	Code	Title	Authors
09:30-14:00	PIH: Individual’s Health	PIH20	A targeted literature review of the economic burden associated with polycystic ovary syndrome	Rajora P, Goli N, Savner R, Singh A, Bhutani MK

Issue Panel

Time	Code	Title	Moderator	Panelists	Location
08:30-09:30	IP19	How effective are managed access agreements as a vehicle for earlier reimbursement in the presence of uncertainty? Lessons from the new Cancer Drugs Fund	Ron Akehurst	Jennifer M Lee, Stephen Palmer, Steve Williamson	C1 M0

Podium Presentation

Time	Code	Title	Authors	Location
14:15-14:30	RW2	Methodological approaches for incorporating real-world overall survival data into long-term survival estimates: case study of a NICE technology appraisal in extensive-stage small-cell lung cancer	Connor S, Orfanos P, Flahavan E, Patterson K, Lee D	C1 M4

Stand C3-046

Email businessdevelopment@bresmed.com to arrange a meeting